DMT1 silencing appears to shift the oncogenic high-TfR/low-FPN phenotype of MDA-MB-231 cells to a low-TfR/high-FPN breast tumor suppressor phenotype [61]. This evidence concerns the gene SLC11A2 and breast neoplasm.